Dr Patrick Tan Hock Siew

AMR IMPACT THEME
  • AMR Therapeutic Solutions
  • AMR Evolution and Protective Microbiomes
EXPERTISE
  • Molecular Microbiology
  • Molecular Mechanism of AMR
  • Aptamer Technology

Dr. Patrick Tan Hock Siew obtained his PhD in Biology (Molecular Microbiology) from the University of Wuerzburg, Germany, in 2017. He is currently a Senior Lecturer at Monash University Malaysia. He serves as the Program Director for the Bachelor of Science program and Deputy Director of the Monash University Malaysia Genomics Platform (MUMGP). His academic journey at Monash University Malaysia began in 2018 as a Scholarly Teaching Fellow, followed by an appointment as Lecturer in 2019.

Dr. Tan's research addresses the global challenge of AMR by integrating quantitative, multiomics approaches with innovative diagnostic and therapeutic strategies. He has demonstrated significant success in securing both national and international research funding. His impactful work has produced award-winning innovations protected by intellectual property, such as the CampySalDeTECT rapid detection kit and APBiotics, an aptamer-based antimicrobial agent. These innovations have garnered international accolades, including Silver and Gold medals at the International Invention, Innovation, and Technology Exhibition (ITEX).

His research investigates how integrated multiomics approaches can unveil the regulatory networks and evolutionary dynamics driving AMR. He also designs modular, nucleic-acid-based aptamers to detect and counteract emerging bacterial pathogens rapidly. Dr. Tan is currently expanding his research into phage biology and engineering to develop phage-based therapies to complement existing aptamer strategies and open new therapeutic pathways.

AMR FOCUS
  • Integrating multiomics approaches to understand the regulatory networks and evolutionary dynamics driving AMR.
  • Investigating AMR transmission mechanisms, including surveillance in environments like wastewater.
  • Designing and developing aptamers for the rapid detection and potential inhibitors of bacterial pathogens.
  • Expanding research into phage biology and engineering, harnessing bacteriophages to counteract AMR and complement aptamer strategies.
IMPACT
  • Insights into AMR evolution and transmission dynamics, informing new intervention, surveillance, and control strategies.
  • Development of novel aptamer-based rapid diagnostics and non-antibiotic therapeutics to combat emerging pathogens.
  • Innovative phage-based therapies as alternatives or complements to antibiotics for treating multidrug-resistant infections.